BENTEN ET AL. v. KESSLER, COMMISSIONER, FOOD AND DRUG ADMINISTRATION, ET AL.
No. A-40
Supreme Court of the United States
July 17, 1992
505 U.S. 1084
Petitioner Leona Benten wants to use RU-486, a drug not approved by the Food and Drug Administration (FDA), in order to induce a nonsurgical abortion. She tried to import a single dosage of the drug for that purpose, but respondent federal officials confiscated her supply at airport customs. Petitioners filed suit in the District Court for the Eastern District of New York in order to compel the immediate return of the drug to Benten. The District Court entered a preliminary injunction granting this remedy. Respondents appealed, and the Court of Appeals for the Second Circuit stayed the injunction pending the appeal. Petitioners have filed an application to vacate the Court of Appeals’ stay. We deny the application.
Petitioners’ application to vacate the Court of Appeals’ July 15, 1992, stay pending respondents’ appeal, presented to JUSTICE THOMAS and by him referred to the Court, is denied.
It is so ordered.
JUSTICE BLACKMUN dissents and would grant the application to vacate the stay.
JUSTICE STEVENS, dissenting.
Whether an undue burden has been imposed on the exercise of a constitutional right depends on the relative significance of the burden, on the one hand, and the governmental interest at stake, on the other.
In this case, applicant Benten‘s constitutionally protected interest in liberty has two components—her decision to terminate the pregnancy and her decision concerning the method of doing so. The Government does not assert any interest in, or right to, burden the former decision. The Government does, however, assert an interest in the latter
Accordingly, I would grant the application.
Notes
The Regulatory Procedures Manual provides in pertinent part as follows:
“In deciding whether to exercise discretion to allow personal shipments of drugs or devices, FDA personnel should consider a more permissive policy in the following situations:
“when the intended use is appropriately identified, such use is not for treatment of a serious condition, and the product is not known to represent a significant health risk.” Ch. 9-71-30(C).
